Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial

作者：Anthony Mills, Giuliano Rizzardini, Moti Ramgopal, Olayemi Osiyemi, Johannes R. Bogner, Debbie Hagins, Roger Paredes, Jacques Reynes, Jürgen K. Rockstroh, Andrew Carr, Feng-Hsiu Su, Stephanie O. Klopfer, Karen Eves, Rebeca M. Plank, Todd Correll, Michelle C. Fox · 发表于：The Lancet HIV · 年份：2024 · DOI：10.1016/s2352-3018(24)00030-4 · 被引用次数：31 · 研究领域：HIV/AIDS drug development and treatment、HIV Research and Treatment、HIV-related health complications and treatments